Biological E and GVK BIO Announce Strategic R&D Partnership
GVK BIO, a leading global Contract Research and Development Organisation (CRDO), and BE Pharmaceuticals Inc (BE Inc), a rapidly growing pharmaceutical company that develops, manufactures and markets complex and critical injectable products, announced a strategic collaboration in drug product development.
As part of the partnership, GVK BIO will develop certain set of injectable products for BE Inc. Development work will include Pre-Formulation studies, Formulation Development, Analytical Method Development and Technology Transfer to a BE facility. The goal of the collaboration will be the successful regulatory submissions and marketing authorizations for the products in the US, Europe and RoW markets.
“GVK BIO’s Formulations Development team has the technical expertise and track record to deliver on projects, and we look forward to working with the BE team to accelerate product development timelines and reduce cost to market,” said Manni Kantipudi, Director & Chief Executive Officer, GVK BIO.
“We are excited to work with GVK BIO, an established CRDO,” said Narender Mantena, CEO, Speciality Generic Injectable, BE Pharmaceuticals. “This collaboration will support BE in building a robust pipeline, especially for critical injectable products."
About GVK BIO
GVK BIO, a Contract Research & Development Organization that services the global Pharmaceutical industry is headquartered in Hyderabad, India and has five sites across the globe. Established in 2001, GVK BIO serves large and small pharma clients across the R&D value chain with a focus on speed and quality, ensuring safety and compliance. GVK BIO’s team of over 2200 scientists, are supported by a no-conflict business model, modern facilities, strong customer-centric culture, and focus on bringing their customers’ products to market rapidly and cost effectively. www.gvkbio.com
About Biological E. Limited
Biological E. Limited (BE) is a privately held company established in 1953. BE is a globally focused biopharmaceutical company, which develops, manufactures and markets innovative vaccines and biologics that respond to healthcare needs worldwide. The company’s product development efforts are driven by an internationally experienced management team and the company has several strategic partnerships with leading biotechnology and pharmaceutical companies and research institutes around the world.
BE Pharmaceuticals Inc is a subsidiary of Biological E. Limited and focuses on Speciality Generic Injectables. www.biologicale.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Expands in the Caribbean2.7.2020 16:30:00 EEST | Press release
Andersen Global announced it entered into a Collaboration Agreement with San Juan, Puerto Rico-based, full-service tax firm BDO Tax LLC, marking the organization’s debut in the region. Founded in 2000, BDO Tax LLC is led by Managing Partner Gaby Hernandez and supported by more than 140 professionals. It provides an array of tax and business advisory services to more than 3,000 clients, including transfer pricing, private client services, transaction advisory, government contracting, accounting services and tax compliance with a specific focus on international tax and inbound tax advisory. “As a former Arthur Andersen professional, I appreciate the importance and impact of working with like-minded individuals who share similar values and commitment to their clients,” Gaby said. “Collaborating with Andersen Global enhances our ability to deliver seamless coverage globally and provide a more comprehensive range of services.” “Gaby has built one of the strongest practices in the region and
Skilling Launches MT42.7.2020 16:07:00 EEST | Press release
Forex and CFD online trading platform Skilling reached another significant milestone this year with the integration and launch of trading platform MetaTrader 4 (MT4). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005309/en/ Skilling Launches MT4 (Photo: Business Wire) Founded in 2016, Skilling introduced their proprietary trading platform in 2018, and in January 2020 they announced the launch of the industry’s first seamless integration with Spotware’s cTrader. With their acquisition of FSA Seychelles license earlier this year, Skilling can now offer MT4 to its current and new clients on a global level. “We have worked tirelessly to launch the renown MetaTrader 4, also known as MT4, the electronic trading platform widely used by online retail foreign exchange traders. Today, we are proud to finally be able to offer our advanced traders a highly customizable platform with many advanced tools and functions, such as MQL4
Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast2.7.2020 16:05:00 EEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, and Peak, Istanbul-based creator of Toon Blast and Toy Blast, announced today that the companies have closed the transaction under which Zynga acquired all of the issued and outstanding common shares of Peak for a total purchase price of approximately $1.85 billion comprised approximately of equal contributions of cash and Zynga common stock. Peak brings to Zynga a renowned, talented team and two forever franchises, Toon Blast and Toy Blast, that have consistently ranked within the top 10 and top 20 U.S. iPhone grossing games for the past two years, respectively. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200702005008/en/ Zynga Closes Transformational Acquisition of Istanbul-based Peak; Expands Forever Franchise Portfolio with Toon Blast and Toy Blast (Graphic: Business Wire) Peak will continue to be led by founder and Chief Executive Officer Sidar
Smiths Detection launches iCMORE algorithms for lithium batteries and dangerous goods for HI-SCAN 10080 XCT2.7.2020 12:00:00 EEST | Press release
Smiths Detection, a leading detection and security company, has launched iCMORE detection algorithms for lithium batteries and dangerous goods for use by its HI-SCAN 10080 XCT scanner, becoming its first explosive-detection system (EDS) to offer these options. The algorithms enhance the scanner’s detection capabilities by helping identify lithium batteries, flammable liquids and solids, and compressed and liquefied gasses, which can pose a risk should they ignite or explode. With iCMORE, Smiths Detection can now reliably and accurately detect potentially dangerous lithium batteries, alongside other dangerous goods, across both its conventional X-ray and its EDS technologies. The iCMORE lithium batteries and dangerous goods algorithms are complementary adaptions to existing screening technology. Although the screening of dangerous goods is not yet mandatory in hold-baggage and air-cargo screening, the increased level of safety for passengers, staff and assets is a key driver for the imp
EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients With COVID-19 Associated Acute Respiratory Distress Syndrome2.7.2020 11:00:00 EEST | Press release
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, today announced that the U.S. Food & Drug Administration (FDA) has approved a randomized, double-blind, placebo-controlled Phase 3 clinical trial protocol to evaluate the safety and efficacy of intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS). Siltuximab is a monoclonal antibody that directly neutralizes interleukin (IL)-6, an inflammatory cytokine detected at elevated levels in multiple inflammatory conditions, including COVID-19. It specifically binds to IL-6, thereby inactivating IL-6 induced signalling. Lee Morley, Chief Executive Officer, EUSA Pharma, said: “Since the start of the pandemic, a growing body of evidence has been published highlighting that COVID-19 associated ARDS may exhibit features of systemic hyperinflammation, resulting from excessive cytokine production – the so-called ‘cytokine storm’ – w
Deenova Multiplies its Pharmacy Automation Market Presence into 7 European Countries2.7.2020 10:34:00 EEST | Press release
Deenova reported today its 2020 step-by-step but relentless continued geographic expansion into Austria, Belgium, France, Germany, Portugal, Spain, and Switzerland, with three new and seasoned business development staff totaling 66 years of healthcare industry experience. Christophe Jaffuel, Deenova’s International Business Development Director, stated: “I am extremely pleased to add Carlos Duran (formerly from Becton Dickinson-Carefusion-Rowa), Thierry Geraud (previously from Becton Dickinson-Carefusion-Pyxis) and Hilmi Sunay (recently from Omnicell-Health Robotics and Arxium-IHS Riva) to an already strong Deenova sales team. These 3 extremely talented and experienced individuals joined Deenova because of its unique technology and business approach to R.O.I., and total service solutions proven in the health care industry. I was equally impressed with Deenova’s demonstrated results when I joined the company 6 months ago, witnessing first-hand how Deenova simultaneously improves patient
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom